[Therapeutic efficacy of nicergoline in ophthalmology. Fluorescence retinographic study (author's transl)].
10-Methoxy-1,6-dimethyl-ergolin-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) administered intravenously (8 mg) in a group of 10 healthy subjects caused a reduction of the arm-retina circulation time and a reduction of the ocular tone. The therapeutic effectiveness in 37 patients with various eye diseases was tested by administering nicergoline p.o. at a dose of 30 mg/day for 30 days and 20 mg/day as maintenance dose for 60-120 days. Positive results, in various percentages, were observed in cases of arterial obstructions, venous thrombosis, diabetic retinopathies, senile macular degenerations, papilla ischaemic oedema, central serous chorioretinopathies. Nicergoline caused no subjective or objective undesired effects.
D000328:Adult; D000368:Aged; D004873:Ergolines / Q000627:therapeutic use*; D005128:Eye Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D009530:Nicergoline / Q000627:therapeutic use*; D011859:Radiography
D004873:Ergolines; D009530:Nicergoline
Therapeutische Wirksamkeit von Nicergolin in der Ophthalmologie. Fluoreszenzretinographischer Beitrag.